Disease Site-Specific Outcomes in p16-Positive Non-Oropharyngeal Mucosal Head and Neck Cancer - Scorecard - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Outcomes Based on Disease Site in p16-Positive Non-Oropharyngeal Mucosal Head and Neck Squamous Cell Carcinoma

  • By

  • Revadhi C. Chelvarajah

  • Lessandra Y. S. Chee

  • Jie Su

  • Brian O'Sullivan

  • Christopher M. K. L. Yao

  • Enrique Sanz-Garcia

  • Stephen M. Smith

  • Ilan Weinreb

  • Scott Bratman

  • B. C. John Cho

  • Ezra Hahn

  • Andrew Hope

  • Ali Hosni

  • John Kim

  • Andrew McPartlin

  • Nauman Malik

  • Chiaojung Jillian Tsai

  • John de Almeida

  • Anna Spreafico

  • Li Tong

  • Shao Hui Huang

  • John N Waldron

  • March 12, 2026

Share

Clinical Scorecard: Outcomes Based on Disease Site in p16-Positive Non-Oropharyngeal Mucosal Head and Neck Squamous Cell Carcinoma

At a Glance

CategoryDetail
ConditionNon-Oropharyngeal Mucosal Head and Neck Squamous Cell Carcinoma
Key Mechanismsp16-positive status as a surrogate for HPV-driven tumors
Target PopulationPatients with non-oropharyngeal HNSCC
Care SettingTertiary cancer center

Key Highlights

  • p16-positive status is associated with variable outcomes in non-oropharyngeal HNSCC.
  • Testing for p16 was performed in 15% of patients, revealing a 20% positivity rate.
  • Improved outcomes were noted in laryngeal and hypopharyngeal cancers, but not consistently across all sites.

Guideline-Based Recommendations

Diagnosis

  • p16 immunohistochemistry testing should be performed for selected non-oropharyngeal HNSCC cases.

Management

  • Curative treatment options include primary surgery or primary radiotherapy with or without chemotherapy.

Monitoring & Follow-up

  • Survival outcomes should be linked with population cancer registries for comprehensive tracking.

Risks

  • Divergent findings regarding p16-positive status may complicate prognostic interpretations.

Patient & Prescribing Data

3061 consecutive non-oropharyngeal HNSCC patients identified.

Treatment included surgery and radiotherapy, with p16 testing performed at clinician discretion.

Clinical Best Practices

  • Utilize p16 IHC as a routine test for non-oropharyngeal HNSCC with atypical risk factors.
  • Ensure adherence to CAP and ASCO guidelines for p16 testing.

Related Resources & Content

Original Source(s)

Disease Site-Specific Outcomes in p16-Positive Non-Oropharyngeal Mucosal Head and Neck Cancer

  • by Revadhi C. Chelvarajah, Lessandra Y. S. Chee, Jie Su, Brian O'Sullivan, Christopher M. K. L. Yao, Enrique Sanz-Garcia, Stephen M. Smith, Ilan Weinreb, Scott Bratman, B. C. John Cho, Ezra Hahn, Andrew Hope, Ali Hosni, John Kim, Andrew McPartlin, Nauman Malik, Chiaojung Jillian Tsai, John de Almeida, Anna Spreafico, Li Tong, Shao Hui Huang, John N Waldron

  • March 12, 2026

Related Content

New Podcast Feature: Dr. Geoffrey Young on SurgOnc Today

Join Baptist Health's Dr. Geoffrey Young as he joins Drs. Sonia Cohen and Ashley Holder on the latest episode of SurgOnc Today.

  • by

  • August 28, 2026

  • 1 min
Submental Approach Robotic-Assisted Neck Dissection (SARAND) for Minimally Invasive Bilateral Neck Dissection: A Feasibility Cadaver Dissection Study

Multimodal salvage therapy for locally advanced esophageal cancer recurrence after failed post-ESD surveillance: a case report